AtonRa Partners Decreases Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

AtonRa Partners reduced its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 12.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,102 shares of the company’s stock after selling 3,125 shares during the period. AtonRa Partners’ holdings in Nurix Therapeutics were worth $218,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Charles Schwab Investment Management Inc. increased its position in shares of Nurix Therapeutics by 48.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 568,576 shares of the company’s stock valued at $4,469,000 after purchasing an additional 184,617 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Nurix Therapeutics by 351.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock valued at $58,000 after acquiring an additional 4,367 shares during the period. Kennedy Capital Management LLC boosted its stake in shares of Nurix Therapeutics by 192.7% during the third quarter. Kennedy Capital Management LLC now owns 163,623 shares of the company’s stock valued at $1,286,000 after purchasing an additional 107,719 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Nurix Therapeutics by 40.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 183,923 shares of the company’s stock valued at $1,446,000 after buying an additional 53,429 shares during the period. Finally, ARK Investment Management LLC lifted its stake in shares of Nurix Therapeutics by 23.2% during the 4th quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company’s stock worth $32,972,000 after purchasing an additional 601,952 shares during the last quarter.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. HC Wainwright reduced their target price on shares of Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday, February 20th. Morgan Stanley raised their price objective on shares of Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a research note on Monday, February 26th. Royal Bank of Canada increased their price target on Nurix Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a research report on Thursday, April 11th. Needham & Company LLC reiterated a “buy” rating and issued a $31.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, April 9th. Finally, Wells Fargo & Company decreased their target price on shares of Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Friday, February 16th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $21.33.

Insider Transactions at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 6,812 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $10.02, for a total transaction of $68,256.24. Following the completion of the sale, the chief financial officer now owns 68,333 shares in the company, valued at $684,696.66. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 7.20% of the company’s stock.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX traded down $0.21 during mid-day trading on Tuesday, reaching $12.26. 116,871 shares of the company traded hands, compared to its average volume of 929,614. The stock has a fifty day simple moving average of $13.66 and a 200-day simple moving average of $9.79. The firm has a market cap of $602.59 million, a PE ratio of -4.60 and a beta of 2.06. Nurix Therapeutics, Inc. has a fifty-two week low of $4.22 and a fifty-two week high of $18.12.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Thursday, February 15th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.26). Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. The business had revenue of $15.16 million during the quarter, compared to the consensus estimate of $30.66 million. As a group, analysts predict that Nurix Therapeutics, Inc. will post -3.15 EPS for the current fiscal year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.